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Background: Hypermethylation of DNA is an epigenetic alteration commonly found in colorectal cancer (CRC) and
can also be detected in blood samples of cancer patients. Methylation of the genes helicase-like transcription factor
(HLTF) and hyperplastic polyposis 1 (HPP1) have been proposed as prognostic, and neurogenin 1 (NEUROG1) as
diagnostic biomarker. However the underlying mechanisms leading to the release of these genes are unclear. This
study aimed at examining the possible correlation of the presence of methylated genes NEUROG1, HLTF and HPP1
in serum with tissue breakdown as a possible mechanism using serum lactate dehydrogenase (LDH) as a surrogate
marker. Additionally the prognostic impact of these markers was examined.
Methods: Pretherapeutic serum samples from 259 patients from all cancer stages were analyzed. Presence of
hypermethylation of the genes HLTF, HPP1, and NEUROG1 was examined using methylation-specific quantitative PCR
(MethyLight). LDH was determined using an UV kinetic test.
Results: Hypermethylation of HLTF and HPP1 was detected significantly more often in patients with elevated LDH
levels (32% vs. 12% [p = 0.0005], and 68% vs. 11% [p < 0.0001], respectively). Also, higher LDH values correlated
with a higher percentage of a fully methylated reference in a linear fashion (Spearman correlation coefficient 0.18
for HLTF [p = 0.004]; 0.49 [p < .0001] for HPP1). No correlation between methylation of NEUROG1 and LDH was
found in this study. Concerning the clinical characteristics, high levels of LDH as well as methylation of HLTF and
HPP1 were significantly associated with larger and more advanced stages of CRC. Accordingly, these three markers
were correlated with significantly shorter survival in the overall population. Moreover, all three identified patients
with a worse prognosis in the subgroup of stage IV patients.
Conclusions: We were able to provide evidence that methylation of HLTF and especially HPP1 detected in serum is
strongly correlated with cell death in CRC using LDH as surrogate marker. Additionally, we found that prognostic
information is given by both HLTF and HPP1 as well as LDH. In sum, determining the methylation of HLTF and HPP1
in serum might be useful in order to identify patients with more aggressive tumors.
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Colorectal cancer (CRC) is the third most common cancer
and the fourth most frequent cause of death from cancer
worldwide with about 1.2 million cases and about 633,000
deaths in 2008 [1]. Despite significant advances in the last
decades, especially patients with metastatic disease suffer
from poor prognosis [2]. In addition to new therapeutic* Correspondence: Frank.Kolligs@med.uni-muenchen.de
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unless otherwise stated.options, biomarkers are needed that allow the identifica-
tion of different subgroups of patients potentially benefit-
ting from different treatment regimens and intensity.
In many human cancers aberrant hypermethylation of
CpG islands is a common epigenetic DNA modification
leading to transcriptional silencing of genes that is
already detectable in early stages of carcinogenesis [3].
Genes found hypermethylated in colorectal cancer have
many functions, including mismatch repair, cell-cycle
regulation and cell differentiation [4]. Methylated tumor
DNA cannot only be found in primary colorectal cancerLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinical features of the patient population






Total number of patients 259
Agea Metastatic disease
≤ 65 years 129 (50) M0 170 (66)
> 65 years 130 (50) M1 89 (34)
Sex Tumor graded
Male 145 (56) G1 & G2 132 (51)
Female 114 (44) G3 & G4 117 (45)
Tumor sizeb Localization
T1 15 (6) Colon 122 (47)
T2 48 (19) Sigmoid 47 (18)
T3 153 (59) Rectum 90 (35)
T4 42 (16) UICC stage
Nodal statusc I 51 (20)
N0 137 (53) II 68 (26)
N1 66 (25) III 51 (20)
N2 50 (19) IV 89 (34)
aMean age: 64.8 years.
bTumor size was unknown in 1 case.
cNodal status was unknown in 6 cases.
dTumor grade was unknown in 10 cases.
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serum or stool and potentially be used as biomarkers for
various purposes [5-7]. We have previously described
methylation of the genes neurogenin 1 (NEUROG1) in
serum and HIC1 in stool as diagnostic markers [8,9] and
helicase-like transcription factor (HLTF) and hyperplastic
polyposis 1 (HPP1), also known as transmembrane protein
with EGF-like and two follistatin-like domains 2 (TMEFF2),
as prognostic serum markers [10,11].
NEUROG1 is a basic helix-loop-helix transcription fac-
tor which has been identified as one of the main players in
neurosensory evolution and development, especially of the
inner ear [12]. Moreover NEUROG1 has been described
to be frequently hypermethylated in colorectal cancers
and has been proposed as a marker to classify the CpG-
island methylator phenotype in colorectal cancers [13,14].
HLTF is a transcription factor and a member of the
SWI/SNF family of chromatin-remodeling factors [15].
The physiological function of HLTF has not yet been
fully understood, but evidence for its association with
genesis and progression of cancer exists [16]. Recently
HLTF deficiency has been reported to significantly in-
crease the formation of small intestinal adenocarcinoma
and colon cancer in mice on a Apcmin/+ mutant back-
ground and to be associated with chromosomal instability
[15]. Hypermethylation of HLTF can commonly be found
in all stages of CRC as well as in adenomas and is associ-
ated with tumor size, stage and poor prognosis [17-20].
Besides its occurrence in serum, methylated HLTF has also
been detected in stool samples of CRC patients [21,22].
HPP1 encodes a transmembrane protein containing
epidermal growth factor and follistatin domains. While
reported to function as a tumor suppressor related to
the STAT1 pathway earlier [23], a recently published
study failed to identify tumors in HPP1 mutant mice
[24]. Hypermethylation of HPP1 can be detected already
early in colorectal carcinogenesis [25-27]. Hyperplastic
polyps and ulcerative colitis associated dysplasias as well
as a several other tumor entities, including Barrett’s-
associated esophageal adenocarcinoma, gastric adenocar-
cinoma, bladder cancer, non-small cell lung cancer and
others, frequently showed HPP1 methylation [26-32].
Lactate dehydrogenase (LDH) is essential for anaerobic
glycolysis and reversably converts pyruvate to lactate. Its
expression has been shown to be related to the hypoxia
inducible factor HIF-1 [33-36]. Activation of the HIF
pathway is a common finding in cancers [37,38]. LDH in
serum is a frequently used parameter in clinical routine
and is released upon cell membrane disintegration. Thus,
it is an unspecific marker for tissue damage, e.g. caused by
necrosis. Elevated LDH levels can be found in numerous
diseases including myocardial infarction, hemolysis and
malignancies [39]. Additionally LDH has been reported to
be associated with more aggressive tumors and shortersurvival [40-43] in CRC. In other cancer entities like tes-
ticular cancer [44,45] and aggressive non-hodgkin lymph-
oma [46] elevated LDH levels are used as prognostic
biomarkers. Recently, LDH has been discussed as a pre-
dictive biomarker for anti-angiogenic therapies in colorec-
tal cancer [43,47,48].
Cell death, especially necrosis, is considered to be the
source of circulating cell-free DNA (cfDNA) in cancer
patients [49,50]. However, the exact mechanisms leading
to the release of the tumor markers discussed here with
prognostic (HLTF and HPP1) or diagnostic (NEUROG1)
information have not been examined so far. This study
aimed at investigating a possible correlation of the pres-
ence of the methylated genes NEUROG1, HLTF and HPP1
in serum with tissue breakdown as a possible release
mechanism using serum lactate dehydrogenase (LDH) as
a surrogate marker. Additionally, the prognostic informa-
tion given by these markers was examined.Methods
Patients and serum samples
Pretherapeutic serum samples from 259 patients with
colorectal cancer were included in the study. For these
cases clinicopathologic and follow-up data as well as
pretherapeutic lactate dehydrogenase values were avail-
able. Characteristics of the cohort are shown in Table 1.
All measurements were performed blinded to patient data.
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went the following standardized preanalytical procedure:
All specimens were transported by a shock absorbed tube
mailing system within 15 to 30 minutes after blood drawing
to the central laboratory, followed by centrifugation at
2,000 g at 4°C for 10 minutes. The supernatant serum was
transferred into polypropylene cryotubes and stored frozen
at −80°C. In each case, DNA methylation and lactate de-
hydrogenase levels were determined in the same blood
sample. The study was approved by the ethical committee
of the Medical Faculty of the University of Munich.DNA isolation and bisulfite conversion
The frozen serum samples were thawed at room temperature
and homogenized by smoothly flipping the tube con-
taining the serum. Genomic DNA from 200 μL of each
serum sample was isolated using the High Pure Viral
Nucleic Acid Kit (Roche Applied Science, Mannheim,
Germany) according to the manufacturer’s instructions
and eluted in 50 μl of Elution Buffer. Bisulfite conver-
sion was performed as described previously [11].
Analysis of DNA methylation
Bisulfite-treated DNA was analyzed by a fluorescence-
based, real-time PCR assay, described previously as Methy-
Light [51]. Dispersed Alu repeats were used to control for
DNA amplification and to normalize for input DNA.
Primer and probe sequences are listed in Additional file 1:
Table S1. PCRs were done in 20 μL volumes containing 1x
PCR buffer (Qiagen, Hilden, Germany), 4 mmol/L MgCl2,
250 μmol/L deoxynucleotide triphosphate mixture, 4 μL
bisulfite-treated DNA, 0.05 units/μL Taq DNA polymerase
(HotStar Taq, Qiagen) along with a pair of primers and
probes according to Additional file 1: Table S1. PCRs
were conducted in a Mastercycler® ep realplex4 (Eppendorf,
Hamburg, Germany) using the following conditions: 95°C
for 900 s followed by 50 cycles of 95°C for 30 s, 60°C for
120 s, and 84°C for 20 s. The specificity of all reactions for
methylated DNA was confirmed by separately amplifying
completely methylated and unmethylated human control
DNA (Chemicon, Temecula, CA) with each set of primers
and probes. The percentage of fully methylated reference
(PMR) at a specific locus was calculated as described previ-
ously [51] by dividing the gene/Alu ratio of a sample by
the gene/Alu ratio of fully methylated, bisulfite-treated
DNA (CpGenome™ Universal Methylated DNA, Millipore,
Billerica, MA) and multiplying by 100. A gene was consid-
ered methylated if the percentage of the fully methylated
reference value was > 0.
Determination of LDH
LDH values were determined by a UV kinetic test using
the Beckman Coulter AU 2700 analyser (BeckmanCoulter GmbH, Krefeld, Germany) by the central labora-
tory of the university hospital of Munich. The upper
limit of normal for this assay applied in everyday clinical
routine is 250 U/l in our hospital. LDH levels above this
value were defined as elevated in this study.
Statistical analysis
All statistical analysis was done using SAS 9.3 (SAS
Institute Inc., Cary, NC). Pearson’s χ2 test was used to
explore associations between clinicopathologic features
and categorized variables. Associations between catego-
rized and continuous variables were tested by means of
the Wilcoxon-Mann–Whitney test and correlations be-
tween continuous variables were examined using Spearman
Correlation Coefficients. For evaluation of simultaneous
influence of clinicopathologic features and methylation
markers on LDH values a multivariate logistic regres-
sion model was developed. Overall survival was calcu-
lated from the date of diagnosis of the primary tumor
to the date of death or end of follow-up. Univariate
analysis of overall survival according to gene methyla-
tion status and LDH values was performed using the
Kaplan–Meier method and log-rank tests.
Results
Clinicopathologic features and DNA methylation in serum
A total number of 259 serum samples were analyzed. An
overview of the clinocopathologic characteristics is shown
in Table 1. Methylation of HLTF was detected in 41 cases
(16%), methylation of HPP1 in 57 cases (22%) and methy-
lation of NEUROG1 in 66 cases (25%). The distribution of
PMR values is demonstrated in Additional file 2: Table S2.
HLTF methylation in the serum was significantly corre-
lated with metastatic diseases (p = 0.013) and advanced
tumor stages (p = 0.0489) as well as T4 tumors (T1-3 vs.
T4, p = 0.046). A non-significant trend towards spread to
lymph nodes was observed (N0 vs. N1-2, p = 0.050). HPP1
methylation in serum was significantly correlated with lar-
ger tumor size (p < 0.001), positive nodal status (p < 0.0001),
metastatic disease (p < 0.0001), tumor stage (p < .0001)
as well as higher tumor grades (p = 0.0002). No signifi-
cant correlation between NEUROG1 methylation and
clinicopathologic features existed. The complete distri-
bution of the markers among the clinicopathologic fea-
tures is presented in Table 2.
LDH values ranged from 100 to 1730 U/l with a mean
value of 238 U/l (standard deviation 202 U/l) and a me-
dian value of 185 U/l. A cutoff of 250 U/l, representing
the upper limit of normal of the assay used, was chosen,
resulting in 50 patients (19%) with elevated LDH levels.
These patients suffered more frequently from T4 tu-
mors (T1-3 vs. T4, p = 0.038), nodal and distant metas-
tases (p = 0.0006 and p < 0.0001, respectively) as well as
higher tumor stages (p < 0.0001). Additionally, a non-
Table 2 Distribution of LDH and methylation of HLTF, HPP1 and NEUROG1 among clinicopathologic features
Clinical feature LDH ≥ 250 U/l HLTF methylation HPP1 methylation NEUROG1 methylation
n (%) P n (%) P n (%) P n (%) p
Total positive 50 (19) 41 (16) 57 (22) 66 (25)
Agea
≤ 65 years 31 (24) 18 (14) 31 (24) 36 (28)
> 65 years 19 (15) 0.055 23 (18) 0.410 26 (20) 0.434 30 (23) 0.372
Sex
Male 26 (18) 22 (15) 34 (23) 34 (23)
Female 24 (21) 0.528 19 (17) 0.744 23 (20) 0.528 32 (28) 0.397
Tumor sizea
T1 0 (0) 2 (13) 1 (7) 4 (27)
T2 9 (19) 3 (6) 3 (6) 12 (25)
T3 28 (18) 25 (16) 32 (21) 39 (25)
T4 13 (31) 0.062 11 (27) 0.080 20 (48) <.0001 11 (26) 0.999
Nodal statusb
N0 14 (10) 16 (12) 13 (9) 37 (27)
N1 19 (29) 13 (20) 23 (35) 13 (20)
N2 15 (30) 0.0006 11 (22) 0.139 18 (36) <.0001 16 (32) 0.307
Metastatic disease
M0 13 (8) 20 (12) 10 (6) 48 (28)
M1 37 (42) <.0001 21 (24) 0.013 47 (53) <.0001 18 (20) 0.160
Localization
Colon 25 (20) 22 (18) 33 (27) 38 (31)
Sigmoid 9 (19) 10 (21) 8 (17) 8 (17)
Rectum 9 (19) 0.884 9 (10) 0.151 16 (18) 0.180 20 (22) 0.114
Tumor gradec
G1 & G2 22 (17) 16 (12) 16 (12) 37 (28)
G3 & G4 25 (21) 0.344 23 (20) 0.102 37 (32) 0.0002 27 (23) 0.372
UICC stage
I 6 (12) 4 (8) 2 (4) 16 (31)
II 4 (6) 11 (16) 4 (6) 19 (28)
III 3 (6) 5 (10) 4 (8) 13 (25)
IV 37 (42) <.0001 21 (24) 0.049 47 (53) <.0001 18 (20) 0.486
aTumor size was unknown in 1 case.
bNodal status was unknown in 6 cases.
cTumor grade was unknown in 10 cases.
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patients was found (p = 0.055).
Correlation between LDH and DNA methylation in serum
First we analyzed the correlation of methylation of
HLTF, HPP1 and NEUROG1 with LDH in a binary way.
For this purpose we used a cutoff of LDH at 250 U/l as
mentioned above. For the methylation markers we consid-
ered a PMR > 0 as methylation positive which has been
shown previously to be reasonable for serum methylation
analysis by our and other groups [10,52,53]. In the 50samples with elevated LDH levels, methylation of HLTF,
HPP1, or NEUROG1 was detected in 16 (32%), 34 (68%),
or 12 cases (24%), respectively, compared to 25 (12%), 23
(11%), or 54 (26%) in those 209 samples with normal
LDH levels. Patients with elevated LDH levels revealed
significantly more often methylation of HLTF or HPP1
(p = 0.0005 or p < 0.0001, respectively), whereas no cor-
relation between NEUROG1 methylation and elevated
LDH was found.
We also examined the relation of the methylation
markers between each other. Methylation of HLTF was
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(51% vs. 17%, p < 0.0001). No significant difference in the
frequency of either HLTF or HPP1 methylation was ob-
served between NEUROG1 positive and NEUROG1 nega-
tive cases (32% vs. 24% and 26% vs. 25%, respectively).
In a second step, correlations were analyzed using LDH
as a continous variable without cutoff. In HPP1 positive
samples significantly higher LDH levels were measured
(median 298 U/l vs. 173 U/l, p < 0.0001). Patients with
methylation of HLTF had slightly, but still significantly
higher LDH levels (median 208 U/l vs. 180 U/l, p = 0.0050),
while no difference was found in LDH levels between
NEUROG1 positive and negative samples (median 187 U/L
vs. 184 U/l, p = 0.95). Figure 1 provides a more detailed
view on the distribution of LDH levels among the three
methylation markers.
Additionally, we tested HLTF, HPP1 and NEUROG1 as
continuous variables without cutoff using the PMR values
and calculated univariate Spearman correlation coeffi-
cients. As in the analyses before, HLTF and HPP1 showed
significant correlation with LDH, while NEUROG1 did
not. All linear correlation coefficients and p-values are
presented in Table 3.
Multivariate model
Next, a multivariate model was developed using logistic
regression analysis with LDH values higher than 250 U/l
as target variable. HPP1 and HLTF methylation as binary
parameters, i.e. with a PMR > 0, as well as clinicopatho-
logical features were entered as independent variables.
Only presence of distant metastases and HPP1 corre-
lated significantly and independently with elevated LDH
levels higher than 250 U/l. The odds ratios were 3.1 forFigure 1 LDH values and methylation status of HLTF, HPP1 and NEURmetastatic disease (95% CI 1.3-7.2, p = 0.009) and 9.5 for
HPP1 methylation (95% CI 4.2-21.9, p < 0.0001).
Survival analysis
We earlier reported methylation of HLTF and HPP1 to
be independent prognostic markers in metastastatic
colorectal cancer [11]. On the other hand, elevated LDH
levels have been described to be linked to shorter
survival [54]. Thus we compared methylation of HLTF
and HPP1 with LDH as prognostic factors in our patient
population.
As reported earlier [11] methylation of HLTF and HPP1
was associated with a higher mortality. In the current
study, the median survival was 6.4 years (95% CI 4.9-9.0)
and 8.0 years (95% CI 6.1-11.2) for HLTF- and HPP1-
negative cases compared to 3.7 years (95% CI 1.1-5.2) and
1.2 years (95% CI 0.9-1.9) in case of positivity for HLTF or
HPP1 methylation (p = 0.0008 and p < 0.0001), respect-
ively (Figure 2A, 2B). LDH levels above a cutoff of 250 U/l
were associated with shorter overall survival (median
survival 1.1 years, 95% CI 0.9-2.0) compared to low
LDH levels (median survival 7.2 years, 95% CI 5.6-9.6)
(p < 0.0001) (Figure 2C).
Next, we evaluated the prognostic significance strati-
fied by tumor stage. For patients with UICC stage I-III
no significant difference in overall survival, neither for
LDH (p = 0.41) nor for HLTF and HPP1 (p = 0.41 and
p = 0.08, respectively), was found. However, in stage IV
HLTF methylation positive patients showed a median
survival of 0.86 years (95% CI 0.5-1.2) versus 1.6 years
(95% CI 1.2-2.3) for HLTF negative cases (p = 0.0081;
Figure 2D). For HPP1 positive and negative cases the
median survival was 1.0 years (95% CI 0.6-1.4) andOG1 (as binary variables, cutoff PMR > 0).
Table 3 Linear Spearman correlation coefficients for the
percentage of fully methylated reference (PMR) of HLTF,
HPP1 and NEUROG1, and LDH levels among each other
PMR HLTF PMR HPP1 PMR NEUROG1 LDH
PMR HLTF 1.0 - - -
PMR HPP1 0.32 (p < .0001) 1.0 - -
PMR
NEUROG1
0.05 (p = 0.41) −0.00 (p = 0.97) 1.0 -




Figure 2 Kaplan-Meier plots of overall survival. A-C: Overall survival for
high LDH levels > 250 U/l (C), respectively. D-F: Overall survival for stage IV
(E) and high LDH levels > 250 U/l (F), respectively.
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Figure 2E). For LDH, elevated levels > 250 U/l were as-
sociated with shorter median survival (1.0 years, 95%
CI 0.6-1.2, vs. 1.8 years, 95% CI 1.3-2.5; p = 0.0002;
Figure 2F).
Discussion
In this study we examined the correlation between cell
damage using LDH as a surrogate marker and the
methylation status of three genes which have previ-
ously been proposed as prognostic (HLTF, HPP1)
[10,11] or diagnostic (NEUROG1) [8] biomarkers for
patients with CRC.
Our data confirm our previous findings that methyla-
tion of HLTF or HPP1 in serum is found more often inD
E
F
all patients according to methylation status of HLTF (A), HPP1 (B) and
patients patients according to methylation status of HLTF (D), HPP1
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cially in those with distant metastases, whereas no cor-
relation between methylation of NEUROG1 and any
clinicopathologic data was found. While methylation of
HLTF was only correlated with metastastatic disease,
methylation of HPP1 was also associated with local
tumor extent and nodal status as well as tumor grade
with high statistic significance.
It is well known that patients with elevated serum
levels of LDH tend to have more aggressive tumors and
a shorter survival time [40-43]. Consistent with the lit-
erature high LDH levels in our data were significantly
correlated with advanced tumor stages as well as nodal
and distant metastases. Trends towards larger tumor size
and younger age were observed but did not reach statis-
tical significance.
Cell death associated mechanisms like apoptosis or, es-
pecially in cancer, necrosis have been suggested as main
sources for cell-free DNA (cfDNA) in the blood, but
other mechanisms like physiological active release have
been described as well (for reviews see refs. [49,50]). In
this study we found methylation of HLTF and, even to a
higher degree, HPP1 to be correlated with elevated LDH
levels. This finding was robust, as it was confirmed by
different statistical methods. Given that elevated LDH
indicates cell membrane damage, this observation might
be a hint that methylated HLTF and HPP1 DNA is re-
leased by tumor cells undergoing cell death. The fact
that necrosis tends to be found more often in larger,
more aggressive tumours and advanced cancer stages
[55,56], which was likewise the case for LDH as well as
methylated HLTF and HPP1 in our data, also suggests
an interrelation.
For NEUROG1, on the other hand, hypermethylation
in serum was detectable independently of LDH levels
and tumor stage. This is consistent with earlier analyses
revealing methylation of NEUROG1 in primary tissue
not to be associated with tumor stage (A.P. and F.K.,
data not published). Hence the observed correlation be-
tween DNA methylation in serum and LDH seems not
to be linked to global methylation levels and cell death
alone. Besides the methylation status of distinct genes,
other parameters influencing this observation might in-
clude DNA integrity and stability of the respective seg-
ments as well as still unknown factors. Therefore it
seems likely that tumor cell death might not be the only
mechanism by which methylated tumor DNA is released
to the blood.
In addition to the correlation analysis we examined
the prognostic significance of the methylation markers
HPP1 and HLTF as well as of LDH. All three markers
were significantly associated with worse overall survival.
This could be attributed to the fact that all three
markers are found more frequently in advanced cancerstages. However, earlier analyses [11] as well as the sur-
vival data presented here furthermore divide patients
with already metastasized disease into two subgroups
with better or worse prognosis, respectively.
Conclusion
In conclusion we were able to provide evidence that methy-
lation of HLTF and especially HPP1 detected in serum is
strongly correlated with cell death in colorectal cancer using
LDH as surrogate marker. However, this finding was specific
for those two genes and did not occur for NEUROG1, sug-
gesting that mechanisms other than release by membrane
disintegration could be responsible for the occurrence of
cell-free DNA in blood of CRC patients. Additionally, we
found that prognostic information is given by both HLTF
and HPP1 as well as LDH. In sum, determining the methy-
lation of HLTF and HPP1 in serum might be useful in order
to identify patients with more aggressive tumors. Future re-
search needs to further clarify the underlying biological
mechanisms and to validate methylated cell-free circulating
DNA as a biomarker for colorectal cancer.
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